The prognostication of colorectal cancer (CRC) has traditionally relied on staging as defined
by the Union for International Cancer Control (UICC) and American Joint Committee on …

Colon cancer is the third most common cancer worldwide. Most colorectal cancer
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …

Human epidermal growth factor receptor 2 (HER2) is a well-known oncogenic driver in
different tumors and an approved therapeutic target in breast and gastroesophageal cancer …

PURPOSE To determine the predictive and prognostic value of the consensus molecular
subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene expression …

High inter-patient variability and high spatial heterogeneity are features of colorectal cancer
(CRC). This may influence the molecular characterization of tumor tissue, now mandatory for …

To define differences in tumor microenvironment (TME) immune phenotypes between right
and left colorectal cancers (CRCs) and explore their therapeutic implications. Gene …

Colorectal cancer (CRC) is the third most common malignancy worldwide. Surgery remains
the most important treatment for non-metastatic CRC, and the administration of adjuvant …

Studies have shown that the prevalence of RAS and BRAF mutations may differ by tumor
sidedness among metastatic colorectal cancer (mCRC) patients. Both mutation status and …

Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct
mutational profile, characterized by oncogenic BRAF mutations and aberrations in mismatch …

PURPOSE To examine the association of gain-of-function (GOF) and non–gain-of-function
(non-GOF) TP53 mutations with prognosis of metastatic right-sided (RCC) versus left-sided …